observational

This study collects body composition measurements and compares them with breast reconstruction outcomes. It is an observational study, not a trial of cancer treatment.

This registry follows people receiving approved antibody-linked drugs as part of routine breast cancer care. It studies outcomes when these drugs are used in sequence without assigning the treatment.

FLEX links breast tumor gene-expression tests with clinical outcomes. It is a registry for studying new patterns in the data, rather than assigning a new treatment.

This study evaluates using MRI to plan breast radiation treatment. It examines whether the scans can be incorporated into routine planning and improve it.

PLUMB follows people with metastatic lobular breast cancer and collects clinical data and samples. It aims to improve how treatment response is measured for this cancer subtype.

This observational study follows symptoms and quality of life in people whose breast cancer has spread to the brain or its coverings. It examines how these experiences relate to care decisions.

QuantifyHER evaluates more precise ways to measure HER2 in tumors. It asks whether these measurements help distinguish people who respond to trastuzumab deruxtecan from those who do not.

This registry collects clinical information, blood and tumor samples from people with recurrent or metastatic breast cancer. It aims to understand tumor spread and differences in treatment response.

SCAN-B is a Swedish study that reads the genes of almost every new breast cancer diagnosed in the south of the country and follows what happens to the patients. It is not a treatment trial; it is the population cohort that many triple-negative subtype and biomarker findings are checked against.

SYNERGY-AI evaluates an AI-assisted service for matching people with cancer to clinical trials. It studies matching and enrollment, not the effectiveness of a particular cancer drug.